Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01671111 · ClinicalTrials.gov registry record · Phase 2
Study for Transfusionally Iron Overloaded Children, Adolescents and Adults Using FBS0701 (SSP-004184)
A Phase 2 study, sponsored by Shire.
- Terminated
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT01671111 is a Phase 2 study that was terminated before completion, run by Shire. The registered enrollment target is 30 participants.
The verdict
NCT01671111, a Phase 2 study, was terminated before completion, sponsored by Shire.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this extension study is to evaluate SSP-004184AQ in patients with transfusional iron overload and to provide data on long term safety and efficacy. SSP-004184AQ is an iron chelator under development for chronic daily oral administration to patients with transfusional iron overload
Interventions
- DRUG SSP-004184AQ
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2012-08-14 |
| Est. Completion | 2014-04-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01671111
The ClinicalTrials.gov registry entry for NCT01671111 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SSP-004184AQ is the first listed.
NCT01671111 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01671111 about?
NCT01671111 is a clinical study titled "Study for Transfusionally Iron Overloaded Children, Adolescents and Adults Using FBS0701 (SSP-004184)". The purpose of this extension study is to evaluate SSP-004184AQ in patients with transfusional iron overload and to provide data on long term safety and efficacy. SSP-004184AQ is an iron chelator under development for chronic daily oral administration to patients with transfusional iron overload
What is the current status of trial NCT01671111?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2012-08-14. Estimated completion is 2014-04-24.
What interventions are being tested in trial NCT01671111?
The interventions under investigation include: SSP-004184AQ (DRUG).
Who is sponsoring clinical trial NCT01671111?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.